What it is
A simple, three-part package combining screening, preventive treatment and community adherence support significantly cuts deaths among people starting HIV treatment with advanced disease.
Why it matters
Cryptococcal meningitis can kill within days and often goes undetected until too late, making the start of HIV treatment one of the most dangerous moments for people with advanced disease. Before REMSTART, routine clinics had no simple way to catch it early.
The story
The EDCTP-funded REMSTART trial, an open-label, randomised controlled trial run in Tanzania and Zambia between 2012 and 2013, tested whether combining cryptococcal antigen (CrAg) screening, preventive fluconazole treatment and short-term community adherence support could reduce mortality among adults starting antiretroviral therapy (ART) with advanced HIV disease [1].
Participants who received the package had significantly lower mortality than those on standard care: a 28% reduction in deaths. [2]. Conducted within routine public-sector HIV clinics rather than a specialist research setting, the trial gave health authorities direct evidence that the approach worked under real-world conditions.
In 2017, the World Health Organization's guidelines on advanced HIV disease [3] recommended that everyone presenting with advanced HIV disease receive a package of screening, prophylaxis, rapid ART initiation and intensified adherence support, building on REMSTART’s results and data. WHO’s 2025 guidance [4] retained this recommendation.
The trial also shaped policy in its own participating countries. Zambia's national advanced HIV disease guidelines [5] now require cryptococcal screening for every patient, built directly on REMSTART's findings. In Tanzania, the follow-on TRIP project [6] adapted the approach for 24 sites, feeding into a national screening plan [7] while the Southern African HIV Clinicians Society's 2019 guideline [8] draws on the trial to recommend both screening and community-based adherence support for all patients with severely weakened immune systems. [9]
REMSTART’s findings also shaped subsequent research efforts. The EFFECT trial, running in Tanzania and South Africa, built on the trial’s results to design a new phase III trial testing fluconazole plus flucytosine [10]. In parallel, health economists used evidence from REMSTART to demonstrate the cost-effectiveness of the treatment package [11][12]. Beyond the trial countries, studies in Uganda [13] and Zimbabwe [14] evaluated national and pilot CrAg screening programmes, contributing further evidence on the feasibility and implementation of cryptococcal screening strategies.
The story of REMSTART is one of early detection and prevention. Together with advances in the treatment of cryptococcal meningitis, such as those demonstrated by the EDCTP-funded AMBITION-cm trial [15], these approaches address different points along the same pathway, helping prevent advanced disease from becoming fatal and making treatment simpler when severe cryptococcal disease occurs.
Sources:
[3] Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy | WHO
[4] WHO guidelines on the management of advanced HIV disease | WHO
[5] Guidelines for management of advanced HIV disease in Zambia | Ministry of Health, Zambia
[6] TRIP: Translating Research Into Practice | EDCTP
[9] National coverage of reflex cryptococcal antigen screening: a milestone achievement | S Afr Med J
[15] Simpler treatment for HIV-associated cryptococcal meningitis | Global Health EDCTP3
Related links
New and better medical solutions already saving and improving lives
RTS,S and R21/Matrix-M are the first vaccines against malaria and, more broadly, against any parasitic disease. Both vaccines stimulate an immune response that prevents malaria infection.
Coartem® Baby is the first approved malaria treatment specifically designed for newborns and young infants weighing 2 to less than 5 kg. It is a dissolvable tablet that can be mixed with breast milk, has a sweet cherry flavour to make administration easier, and delivers precise dosing.
Triomune Baby/Junior became the first fixed-dose combination medicine developed specifically for children with HIV and paved the way for additional improved combination therapies for first- and second-line HIV treatment in children.
This new fixed-dose combination therapy of albendazole/ivermectin targets five types of parasitic worms (four soil-transmitted helminth infections and lymphatic filariasis), which will significantly improve the efficiency and cost-effectiveness of large-scale interventions.
Arpraziquantel is the first child-friendly medicine in an oro-dispersible formulation to treat and cure schistosomiasis. It is easy to administer and adapted for rural and tropical settings, offering high efficacy with minimal side effects.
Fexinidazole Winthrop and Acoziborole Winthrop are two new oral treatments for human African trypanosomiasis (HAT), known as sleeping sickness. Fexinidazole is the first all-oral therapy, while Acoziborole is the first single-dose, one-day treatment for the most common form of the disease.
This new therapy, a single high-dose of liposomal Amphotericin B, is as effective as the traditional week-long regimen, easier to administer, and causes fewer side effects. It is now the WHO-recommended therapy for cryptococcal meningitis.
A simple, three-part package combining screening, preventive treatment and community adherence support significantly cuts deaths among people starting HIV treatment with advanced disease.
Dihydroartemisinin-piperaquine (DHAPQ) is an artemisinin-based combination therapy (ACT) used to treat uncomplicated malaria.
Molbio Truenat, with MTB-Plus and RIF-Dx assays, is a portable, battery-powered molecular diagnostic tool for tuberculosis (TB) testing directly in primary health care settings.
Pyramax® and Eurartesim® are two established antimalarial medicines whose safety and efficacy have been progressively expanded through EDCTP-supported research to reach more patient groups who lack specific treatments, such as children, pregnant women, and patients requiring re-treatment.
The PredART trial showed that prednisone, a common and inexpensive steroid drug used to treat Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome (TB-IRIS), can also be used to prevent it.
A three-drug antiretroviral regimen given to HIV-positive women in late pregnancy and through breastfeeding cuts HIV transmission to babies safely, without requiring mothers to stop breastfeeding.
Our added value for Europe
EDCTP boosts Europe’s competitiveness by advancing research excellence, innovation, and public–private cooperation in global health. By supporting late-stage development and Africa–Europe partnerships, it bridges the EU innovation gap and creates new market and investment opportunities.
EDCTP strengthens Europe’s health security by tackling climate-sensitive diseases and antimicrobial resistance, enhancing surveillance, and accelerating medical countermeasures. Its rapid crisis responses, from Ebola to COVID-19, show its agility in protecting Europe and global health.
EDCTP drives Europe’s science diplomacy through fair Africa–Europe partnerships that tackle global health challenges. Its equitable governance and ethical research practices strengthen EU credibility and global influence.
EDCTP strengthens Europe’s leadership in digital health by investing in AI, data, and digital technologies while training researchers in fields like bioinformatics and genomic epidemiology.
EDCTP advances the EU’s human rights goals by promoting ethical, inclusive research that addresses unmet medical needs. It ensures innovations reach vulnerable populations while strengthening local scientific and health systems.
Our added value for Africa
EDCTP improves health and prosperity in Africa by funding clinical research, strengthening local capacities, and empowering African scientists. Its investments reduce the burden of infectious diseases, boost productivity, and support sustainable development across the continent.
EDCTP builds Africa’s capacity to detect, prevent, and respond to outbreaks through training, research, and strong partnerships. Its work accelerates vaccine and diagnostic development and reinforces the continent’s health resilience.
EDCTP strengthens Africa’s clinical research ecosystem by investing in skills, infrastructure, and regulatory systems. Initiatives like CTCAN and PACTR connect researchers and regulators, expanding quality trials and fostering local leadership.
EDCTP strengthens Africa-led health partnerships with organisations like Africa CDC and WHO AFRO, aligning research and investment with continental priorities. As an AU–EU Innovation Agenda partner, it builds skills, fosters co-investment, and drives sustainable cooperation.
EDCTP promotes health equity by developing practical solutions for underserved communities, including newborns and children, women, urban poor and rural communities. It funds accessible technologies and digital tools that expand healthcare reach and improve outcomes for those most in need.